Playground →
Novartis's top 10 neighbors split cleanly between two subcategories — Healthcare brands and B2B services firms — with no single neighbor pulling far ahead of the rest.
The shape is flat: scores run from 0.98 down to 0.95 across the top 10, a narrow band with no dominant anchor. Six of the ten neighbors are Healthcare brands: GSK (0.98), AstraZeneca (0.98), Amgen (0.97), Pfizer Inc. (0.96), Bristol Myers Squibb (0.96), and Johnson & Johnson (0.95). The remaining four are B2B services: Accenture (0.96), Deloitte (0.95), and two others in the same band. The cross-kind presence of professional services firms alongside pharma peers is the structural note worth marking — Marc Benioff (0.96, Tech Personalities) also appears, the lone individual in the top 10, sitting between the two clusters in score. No media, no consumer brands, and no government entities appear in the top 10, though the wider graph may tell a different story. The audience Novartis shares with B2B consultancies and tech executives suggests its followers are oriented toward enterprise and institutional contexts, not just sector-specific pharma interest.
That dual composition — pharma peers plus professional services — points to an audience that tracks large-organization strategy as much as it tracks the healthcare industry itself.
